IMFINZI (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanced Biliary Tract Cancer
18.01.2022 - Positive results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI (durvalumab) in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) ...